// App-Quantinova.ai

TPS5088 : Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Sumit Kumar Subudhi

Principal Investigators

  • Joseph J. Maly

  • Lakshminarayanan Nandagopal

  • Elaine Tat Lam

  • Young E. Whang

  • Mukul Minocha

  • Vinita Gupta

  • Xianne Penny

  • Freda Cooner

  • Camila Jhones

  • Andrew Paluch

  • Mark Salvati

  • Margit Janat-Amsbury

  • Tobias Eggert

  • Hosein Kouros-Mehr

  • Anthony M. Joshua

  • Rahul Raj Aggarwal

  • Johann S. De Bono

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Norton Cancer Institute, Louisville, KY, University of Alabama at Birmingham, Birmingham, AL, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, University of North Carolina at Chapel Hill, Chapel Hill, NC, Amgen Inc., Thousand Oaks, CA

  • Amgen Inc, South San Francisco, CA

  • Amgen Inc, Thousand Oaks, CA

  • St Vincents Hospital, Sydney, Australia

  • University of California, San Francisco, San Francisco, CA

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

Locations

  • Australia

  • United Kingdom

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Prostate cancer

  • Leptomeningeal Metastasis

  • Solid malignancies

Biomarkers

  • 18F-fluorodeoxyglucose

  • Prostate specific antigen

  • Folate Hydrolase 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Enzalutamide

  • CB-7598

  • Fludeoxyglucose (18F)

  • taxane

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • N/A

Study Id's

  • NCT04631601

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved